Paratek Pharmaceuticals, Inc., has announced that the US Food and Drug Administration (FDA) has approved Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥9 years. Paratek Pharmaceuticals is headquartered in Boston, MA.
Dosage/administration: The recommended dosage of Seysara is once daily with or without food and is based on the patient’s weight:
• 60 mg for patients who weigh 33-54 kg,
• 100 mg for patients who weigh 55-84 kg,
• 150 mg for patients who weigh 85-136 kg.
Adverse effects: The most common adverse reaction (incidence ≥ 1%) is nausea.
FDA approves Seysara (sarecycline) for the treatment of moderate to severe acne. [news release]. Boston, MA: Paratek Pharmaceuticals, Inc. October 2, 2018. https://www.biospace.com/article/releases/fda-approves-seysara-sarecycline-for-the-treatment-of-moderate-to-severe-acne/. Accessed October 18, 2018.